MCID: RSP003
MIFTS: 74

Respiratory Failure

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Respiratory Failure

MalaCards integrated aliases for Respiratory Failure:

Name: Respiratory Failure 12 29 54 6 42 15 62 17 70
Acute Respiratory Failure 12 54 15 70 32
Chronic Respiratory Failure 12 54 70 32
Respiratory Insufficiency 29 6 70
Acute-on-Chronic Respiratory Failure 12 70
Acute and Chronic Respiratory Failure 12
Chronic Disease of Respiratory System 70
Respiratory Insufficiency/failure 12
Pulmonary Valve Insufficiency 70
Chronic Respiratory Disease 54
Respiratory Tract Diseases 70
Respiratory Abnormality 6
Respiration Disorders 70
Respiratory Disease 54

Classifications:



External Ids:

Disease Ontology 12 DOID:11162
ICD9CM 34 518.81
NCIt 50 C27043
SNOMED-CT 67 65710008
UMLS 70 C0034088 C0035204 C0035229 more

Summaries for Respiratory Failure

MedlinePlus : 42 What is respiratory failure? Respiratory failure is a condition in which your blood doesn't have enough oxygen or has too much carbon dioxide. Sometimes you can have both problems. When you breathe, your lungs take in oxygen. The oxygen passes into your blood, which carries it to your organs. Your organs, such as your heart and brain, need this oxygen-rich blood to work well. Another part of breathing is removing the carbon dioxide from the blood and breathing it out. Having too much carbon dioxide in your blood can harm your organs. What causes respiratory failure? Conditions that affect your breathing can cause respiratory failure. These conditions may affect the muscles, nerves, bones, or tissues that support breathing. Or they may affect the lungs directly. These conditions include Diseases that affect the lungs, such as COPD (chronic obstructive pulmonary disease), cystic fibrosis, pneumonia, pulmonary embolism, and COVID-19 Conditions that affect the nerves and muscles that control breathing, such as amyotrophic lateral sclerosis (ALS), muscular dystrophy, spinal cord injuries, and stroke Problems with the spine, such as scoliosis (a curve in the spine). They can affect the bones and muscles used for breathing. Damage to the tissues and ribs around the lungs. An injury to the chest can cause this damage. Drug or alcohol overdose Inhalation injuries, such as from inhaling smoke (from fires) or harmful fumes What are the symptoms of respiratory failure? The symptoms of respiratory failure depend on the cause and the levels of oxygen and carbon dioxide in your blood. A low oxygen level in the blood can cause shortness of breath and air hunger (the feeling that you can't breathe in enough air). Your skin, lips, and fingernails may also have a bluish color. A high carbon dioxide level can cause rapid breathing and confusion. Some people who have respiratory failure may become very sleepy or lose consciousness. They also may have arrhythmia (irregular heartbeat). You may have these symptoms if your brain and heart are not getting enough oxygen. How is respiratory failure diagnosed? Your health care provider will diagnose respiratory failure based on Your medical history A physical exam, which often includes Listening to your lungs to check for abnormal sounds Listening to your heart to check for arrhythmia Looking for a bluish color on your skin, lips, and fingernails Diagnostic tests, such as Pulse oximetry, a small sensor that uses a light to measure how much oxygen is in your blood. The sensor goes on the end of your finger or on your ear. Arterial blood gas test, a test that measures the oxygen and carbon dioxide levels in your blood. The blood sample is taken from an artery, usually in your wrist. Once you are diagnosed with respiratory failure, your provider will look for what is causing it. Tests for this often include a chest x-ray. If your provider thinks you may have arrhythmia because of the respiratory failure, you may have an EKG (electrocardiogram). This is simple, painless test that detects and records your heart's electrical activity. What are the treatments for respiratory failure? Treatment for respiratory failure depends on Whether it is acute (short-term) or chronic (ongoing) How severe it is What is causing it Acute respiratory failure can be a medical emergency. You may need treatment in intensive care unit at a hospital. Chronic respiratory failure can often be treated at home. But if your chronic respiratory failure is severe, you might need treatment in a long-term care center. One of the main goals of treatment is to get oxygen to your lungs and other organs and remove carbon dioxide from your body. Another goal is to treat the cause of the condition. Treatments may include Oxygen therapy, through a nasal cannula (two small plastic tubes that go in your nostrils) or through a mask that fits over your nose and mouth Tracheostomy, a surgically-made hole that goes through the front of your neck and into your windpipe. A breathing tube, also called a tracheostomy, or trach tube, is placed in the hole to help you breathe. Ventilator, a breathing machine that blows air into your lungs. It also carries carbon dioxide out of your lungs. Other breathing treatments, such as noninvasive positive pressure ventilation (NPPV), which uses mild air pressure to keep your airways open while you sleep. Another treatment is a special bed that rocks back and forth, to help you breathe in and out. Fluids, often through an intravenous (IV), to improve blood flow throughout your body. They also provide nutrition. Medicines for discomfort Treatments for the cause of the respiratory failure. These treatments may include medicines and procedures. If you have respiratory failure, see your health care provider for ongoing medical care. Your provider may suggest pulmonary rehabilitation. If your respiratory failure is chronic, make sure that you know when and where to get help for your symptoms. You need emergency care if you have severe symptoms, such as trouble catching your breath or talking. You should call your provider if you notice that your symptoms are worsening or if you have new signs and symptoms. Living with respiratory failure may cause fear, anxiety, depression, and stress. Talk therapy, medicines, and support groups can help you feel better. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Respiratory Failure, also known as acute respiratory failure, is related to neonatal respiratory failure and adult respiratory distress syndrome, and has symptoms including dyspnea, hemoptysis and apnea. An important gene associated with Respiratory Failure is INPP5E (Inositol Polyphosphate-5-Phosphatase E), and among its related pathways/superpathways are Diseases of metabolism and Surfactant metabolism. The drugs Riluzole and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and liver, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A lung disease characterized by inadequate gas exchange by the respiratory system.

PubMed Health : 62 About respiratory failure: Respiratory (RES-pih-rah-tor-e) failure is a condition in which not enough oxygen passes from your lungs into your blood. Your body's organs, such as your heart and brain, need oxygen-rich blood to work well. Respiratory failure also can occur if your lungs can't properly remove carbon dioxide (a waste gas) from your blood. Too much carbon dioxide in your blood can harm your body's organs. Both of these problems—a low oxygen level and a high carbon dioxide level in the blood—can occur at the same time. Diseases and conditions that affect your breathing can cause respiratory failure. Examples include COPD (chronic obstructive pulmonary disease) and spinal cord injuries. COPD prevents enough air from flowing in and out of the airways. Spinal cord injuries can damage the nerves that control breathing.

Wikipedia : 73 Respiratory failure results from inadequate gas exchange by the respiratory system, meaning that the... more...

Related Diseases for Respiratory Failure

Diseases in the Respiratory Failure family:

Severe Acute Respiratory Syndrome

Diseases related to Respiratory Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1556)
# Related Disease Score Top Affiliating Genes
1 neonatal respiratory failure 33.2 SFTPD SFTPC SFTPB SCGB1A1 NKX2-1 ABCA3
2 adult respiratory distress syndrome 32.8 SFTPD SFTPC SFTPB SCGB1A1 IGHMBP2 ELANE
3 lung disease 32.6 SFTPD SFTPC SFTPB SCGB1A1 NKX2-1 ELANE
4 pneumonia 32.6 SFTPD SFTPC SFTPB SCGB1A1 ELANE
5 pulmonary fibrosis, idiopathic 32.5 SFTPD SFTPC SFTPB SCGB1A1 ELANE ABCA3
6 acute interstitial pneumonia 32.4 SFTPD SFTPC SFTPB ABCA3
7 pulmonary fibrosis 32.4 SFTPD SFTPC ELANE ABCA3
8 pulmonary disease, chronic obstructive 32.2 SFTPD SFTPB SCGB1A1 ELANE
9 surfactant dysfunction 32.2 SFTPC SFTPB ABCA3
10 newborn respiratory distress syndrome 32.2 TTN SFTPD SFTPC SFTPB SCGB1A1 NKX2-1
11 surfactant metabolism dysfunction, pulmonary, 1 32.2 SFTPC SFTPB ABCA3
12 myasthenia gravis 32.2 TTN RYR1 MUSK
13 rigid spine muscular dystrophy 1 32.1 TTN RYR1 GAA
14 myopathy 31.8 TTN-AS1 TTN SFTPC RYR1 MTM1 IGHMBP2
15 bronchopulmonary dysplasia 31.8 SFTPB SCGB1A1 ELANE
16 interstitial lung disease 31.7 SFTPD SFTPC SFTPB NKX2-1 INPP5E ABCA3
17 neuromuscular disease 31.7 TTN-AS1 TTN RYR1 MUSK MTM1 IGHMBP2
18 bacterial pneumonia 31.6 SFTPD SFTPB SCGB1A1 ELANE
19 diaphragmatic hernia, congenital 31.6 SFTPC SFTPB NKX2-1
20 meconium aspiration syndrome 31.6 SFTPB SCGB1A1 ABCA3
21 muscular atrophy 31.4 TTN RYR1 IGHMBP2 DCTN1
22 pulmonary alveolar proteinosis 31.2 SFTPD SFTPC SFTPB
23 pulmonary emphysema 31.2 SFTPD SFTPC ELANE
24 respiratory distress syndrome in premature infants 31.1 SFTPC SFTPB ABCA3
25 idiopathic interstitial pneumonia 31.1 SFTPD SFTPC SFTPB ELANE
26 lung cancer susceptibility 3 31.0 SFTPD SFTPC SFTPB SCGB1A1 NKX2-1
27 ptosis 31.0 RYR1 MUSK MTM1 IGHMBP2 CHAT
28 batten-turner congenital myopathy 31.0 TTN-AS1 TTN RYR1 MTM1 GAA
29 pulmonary interstitial emphysema 30.9 SFTPD SFTPC SFTPB ABCA3
30 tracheal agenesis 30.9 SFTPD SFTPB
31 thymoma 30.9 TTN RYR1 NKX2-1
32 cryptogenic organizing pneumonia 30.7 SFTPD SFTPC
33 congenital myasthenic syndrome 30.7 TTN RYR1 MUSK MTM1 CHAT
34 pulmonary immaturity 30.6 SFTPD SFTPC SFTPB ABCA3
35 interstitial pneumonitis, desquamative, familial 30.6 SFTPD SFTPC SFTPB ABCA3
36 lung benign neoplasm 30.5 SFTPC SCGB1A1 NKX2-1
37 congenital fiber-type disproportion 30.4 TTN RYR1 MTM1
38 multiminicore disease 30.4 TTN-AS1 TTN RYR1
39 lipid pneumonia 30.4 SFTPC SFTPB ABCA3
40 autosomal dominant distal myopathy 30.4 TTN-AS1 TTN
41 pulmonary hemosiderosis 30.4 SFTPB ABCA3
42 muscular disease 30.4 TTN RYR1 MTM1
43 paraquat lung 30.4 SFTPB SCGB1A1
44 nonspecific interstitial pneumonia 30.3 SFTPD SFTPC ABCA3
45 centronuclear myopathy 30.3 TTN-AS1 TTN RYR1 MTM1
46 myopathy, centronuclear, x-linked 30.3 TTN RYR1 MTM1
47 central core disease of muscle 30.2 RYR1 GAA
48 pulmonary valve insufficiency 30.2 PMS2 ABCA3
49 cardiomyopathy, familial hypertrophic, 20 30.1 SFTPB SCGB1A1
50 myopathy, myofibrillar, 9, with early respiratory failure 11.9

Comorbidity relations with Respiratory Failure via Phenotypic Disease Network (PDN): (show top 50) (show all 116)


Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Alcohol Use Disorder
Alcoholic Cardiomyopathy Alcoholic Liver Cirrhosis
Anthracosis Anxiety
Aortic Aneurysm Aortic Valve Disease 1
Asbestosis Aspergillosis
Asthma Bleeding Disorder, Platelet-Type, 11
Bronchiectasis Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiogenic Shock
Chronic Kidney Disease Chronic Pulmonary Heart Disease
Conjunctivitis Conn's Syndrome
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Polyneuropathy
Diaphragm Disease Disseminated Intravascular Coagulation
Dysthymic Disorder Encephalopathy
Esophageal Candidiasis Esophagitis
Familial Atrial Fibrillation Generalized Atherosclerosis
Goodpasture Syndrome Granulomatosis with Polyangiitis
Guillain-Barre Syndrome, Familial Heart Disease
Hepatic Encephalopathy Hypertension, Essential
Hypertensive Encephalopathy Hypertrophic Cardiomyopathy

Graphical network of the top 20 diseases related to Respiratory Failure:



Diseases related to Respiratory Failure

Symptoms & Phenotypes for Respiratory Failure

UMLS symptoms related to Respiratory Failure:


dyspnea; hemoptysis; apnea; respiratory distress; cyanosis; stridor; edema; wheezing; inspiratory stridor; rhinorrhea; snoring; sore throat; cheyne-stokes respiration; coughing; hoarseness; anoxemia; labored breathing; sneezing; expiratory wheeze; inspiratory wheeze; choking sensation; pathological conditions, signs and symptoms; signs and symptoms of ill-defined conditions; pleuritic pain; sinus congestion; other symptoms involving respiratory system and chest; bronchorrhea; neonatal cyanosis; gasping for breath; symptoms involving respiratory system and other chest symptoms; nasal congestion (finding); nasal irritation; neck tightness; larynx pain

MGI Mouse Phenotypes related to Respiratory Failure:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 ABCA3 CHAT CLCN6 DCTN1 ELANE GAA
2 cellular MP:0005384 10.22 CLCN6 DCTN1 GAA IGHMBP2 INPP5E MTM1
3 homeostasis/metabolism MP:0005376 10.22 ABCA3 CHAT DCTN1 ELANE GAA IGHMBP2
4 growth/size/body region MP:0005378 10.21 ABCA3 CHAT GAA IGHMBP2 INPP5E MTM1
5 mortality/aging MP:0010768 10.19 ABCA3 CHAT DCTN1 ELANE IGHMBP2 INPP5E
6 cardiovascular system MP:0005385 10.17 ABCA3 CHAT GAA IGHMBP2 INPP5E MTM1
7 muscle MP:0005369 9.81 CHAT DCTN1 GAA IGHMBP2 MTM1 MUSK
8 respiratory system MP:0005388 9.7 ABCA3 CHAT IGHMBP2 MTM1 MUSK NKX2-1
9 skeleton MP:0005390 9.28 CHAT GAA IGHMBP2 INPP5E MTM1 MUSK

Drugs & Therapeutics for Respiratory Failure

PubMed Health treatment related to Respiratory Failure: 62

Treatment for respiratory failure depends on whether the condition is acute (short-term) or chronic (ongoing) and its severity. Treatment also depends on the condition's underlying cause. Acute respiratory failure can be a medical emergency. It often is treated in an intensive care unit at a hospital. Chronic respiratory failure often can be treated at home. If chronic respiratory failure is severe, your doctor may recommend treatment in a long-term care center. One of the main goals of treating respiratory failure is to get oxygen to your lungs and other organs and remove carbon dioxide from your body. Another goal is to treat the underlying cause of the condition.

Drugs for Respiratory Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 470)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
2
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
3
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
9
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
10
Cisatracurium Approved Phase 4 96946-41-7 62887
11
Beractant Approved Phase 4 108778-82-1
12
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
13
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
14
Adenosine Approved, Investigational Phase 4 58-61-7 60961
15
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
16
Nalbuphine Approved Phase 4 20594-83-6 5311304 5360630
17
Orphenadrine Approved Phase 4 83-98-7 4601
18
Omalizumab Approved, Investigational Phase 4 242138-07-4
19
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
20
Losartan Approved Phase 4 114798-26-4 3961
21
Eprosartan Approved Phase 4 133040-01-4 5281037
22
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
23
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
24
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
27
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
28
Rivaroxaban Approved Phase 4 366789-02-8
29
Ibuprofen Approved Phase 4 15687-27-1 3672
30
Nintedanib Approved Phase 4 656247-17-5 56843413
31
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
32
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
33
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
35
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
36
Enoxaparin Approved Phase 4 9005-49-6 772
37
Digoxin Approved Phase 4 20830-75-5 30322 2724385
38
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
39 Poractant alfa Approved Phase 4 129069-19-8
40
Remifentanil Approved Phase 4 132875-61-7 60815
41
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
42
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
43
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
44
Succinylcholine Approved Phase 4 306-40-1 5314
45
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
46
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
48
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
49
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
50
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440

Interventional clinical trials:

(show top 50) (show all 1668)
# Name Status NCT ID Phase Drugs
1 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
2 Randomized Controlled Trial of Inspiratory Muscle Training in Patients With Stable Hypercapnic Respiratory Failure Due to COPD Unknown status NCT00291460 Phase 4
3 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
4 A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol Unknown status NCT01873521 Phase 4
5 Functional Residual Capacity Guided Alveolar Recruitment Strategy in Patients With Acute Respiratory Failure After Cardiac Surgery Unknown status NCT01280019 Phase 4
6 A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure Unknown status NCT00994552 Phase 4
7 Phase 4, Single Centre, Single Blinded,Prospective Randomised Cross Over Comparison on the Physiological Response of Post Extubation Intensive Care Patients to Non-invasive Ventilation Using Either Air O2 or Heliox21 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
8 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Unknown status NCT03656198 Phase 4 Sterile Water Injection
9 Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Unknown status NCT01513655 Phase 4
10 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
11 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
12 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
13 A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
14 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
15 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
16 Effect of Neuromuscular Blockade Reversal With Sugammadex on Oxygenation, Pain and Arousal States in the Post Anesthesia Care Unit Completed NCT02243943 Phase 4 Sugammadex;Neostigmine
17 Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis Completed NCT00222534 Phase 4 Acetazolamide;Placebo
18 Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation: The PrePARE Trial Completed NCT03026777 Phase 4 intravenous crystalloid fluid, 500 mL
19 Non-Positive Pressure Ventilation in Hypoxemic Patients. A Randomized Study Completed NCT00925860 Phase 4
20 A Randomized Trial to Compare the Effectiveness of Hospital or Ambulatory Approach for Adaptation to Non-Invasive Mechanical Ventilation in Patients With Chronic Respiratory Failure Secondary to Neuromuscular Diseases or Thoracic Cage Alterations Completed NCT00698958 Phase 4
21 Hypercapnic Acute Respiratory Failure: Is the Helmet an Effective Interface?" Completed NCT01645358 Phase 4
22 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients With Cough and Sputum as the Main Symptoms Completed NCT03334916 Phase 4 YMC026;Placebo
23 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
24 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
25 Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
26 Does a Diagnostic Strategy Reduce Duration and Cost of Hospitalization in Patients With Acute Dyspnea? BASEL II Intensive Care Unit Completed NCT00130559 Phase 4
27 Effects of Remifentanil on Breathing Pattern, Respiratory Effort and Gas Exchange in Mechanically Ventilated Patients. Completed NCT00665119 Phase 4 remifentanil;placebo
28 Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation Completed NCT02454582 Phase 4
29 Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure Completed NCT00507533 Phase 4
30 Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS) Completed NCT01443845 Phase 4 Roflumilast;Placebo
31 Effect of a Closed Loop Ventilation Strategy on Reducing the Total Duration of Mechanical Ventilation of Intubated Intensive Care Unit Patients: A Randomized Controlled Trial Completed NCT01472302 Phase 4
32 High-assistance Proportional Assist Ventilation (PAV) vs. Assist-Control Ventilation (ACV) in Early Stage of Critically Ill Patients Completed NCT01204281 Phase 4
33 Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients; Randomized Prospective Study Completed NCT00355732 Phase 4
34 Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial Completed NCT02497729 Phase 4
35 Patients-ventilator Interaction During Sleep: the Role of Humidification. A Pilot Short Term Study Completed NCT01038791 Phase 4
36 Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial Completed NCT02526862 Phase 4
37 Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial Completed NCT00708149 Phase 4 lansoprazole OD;placebo
38 A Randomized Controlled Trial Comparing Two Protocols to Withdraw Non-invasive Ventilation (NIV) After an Episode of Hypercapnic Respiratory Failure Completed NCT00775710 Phase 4
39 Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation Completed NCT00732537 Phase 4 inhaled Nitric Oxide;Oxygen (>90% by hood) - standard therapy
40 A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure. Completed NCT04326920 Phase 4 Sargramostim
41 Multicenter, Randomised Study of the Use of Non-Invasive Ventilation (NIV) Versus Oxygen Therapy (O2) in Reducing Dyspnea in End-stage Solid Cancer Patients With Respiratory Failure and Distress Completed NCT00533143 Phase 4
42 The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine Completed NCT02477293 Phase 4 Hyeonggaeyeongyo-tang
43 Feedback Reports and E-learning to Support Spirometry Test Performance in Dutch Family Practices Completed NCT00962455 Phase 4
44 Short Term Physiological Effects of Nasal High Oxygen Flow vs Low Oxygen Flow and Noninvasive Ventilation (NIV) on Respiratory Mechanics Completed NCT02363920 Phase 4
45 PRO-DEFENSE: Propofol Versus Dexmedetomidine for Sedation in Mechanically Ventilated Patients With Sepsis Completed NCT02203019 Phase 4 Propofol;Dexmedetomidine;Fentanyl
46 The NAPRESSIM Trial. The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine. Completed NCT02885948 Phase 4 Naloxone;Placebo
47 Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant Completed NCT01941524 Phase 4 Poractant alfa instillation;Beractant instillation
48 Interscalene Block on Ventilatory Function After Shoulder Surgery : Evaluation of Single or Continuous Injection Completed NCT01740453 Phase 4 ropivacaine 2 mg/ml
49 Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy - A Randomized Clinical Trial Completed NCT01717222 Phase 4 Intraperitoneal Lignocaine;Intravenous Lignocaine
50 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium

Search NIH Clinical Center for Respiratory Failure

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Glycopyrrolate
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
Oxygen
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR

Genetic Tests for Respiratory Failure

Genetic tests related to Respiratory Failure:

# Genetic test Affiliating Genes
1 Respiratory Insufficiency 29
2 Respiratory Failure 29

Anatomical Context for Respiratory Failure

MalaCards organs/tissues related to Respiratory Failure:

40
Lung, Heart, Liver, Kidney, Spinal Cord, Brain, Bone

Publications for Respiratory Failure

Articles related to Respiratory Failure:

(show top 50) (show all 30632)
# Title Authors PMID Year
1
Waterproofing spray-associated pneumonitis review: Comparison with acute eosinophilic pneumonia and hypersensitivity pneumonitis. 61 42
33725891 2021
2
Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. 42 61
33726819 2021
3
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
4
Assessment of Respiratory Function in Infants and Young Children Wearing Face Masks During the COVID-19 Pandemic. 42
33651109 2021
5
Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. 61 54
19824815 2010
6
Inherited surfactant deficiency caused by uniparental disomy of rare mutations in the surfactant protein-B and ATP binding cassette, subfamily a, member 3 genes. 54 61
19647838 2009
7
Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. 61 54
19539245 2009
8
Interfamilial phenotypic heterogeneity in SMARD1. 54 61
19157874 2009
9
Association of polymorphisms in the human surfactant protein-D (SFTPD) gene and postnatal pulmonary adaptation in the preterm infant. 61 54
18785967 2009
10
[Lung diseases associated with inherited disorders of surfactant metabolism]. 61 54
18804975 2008
11
Surfactant protein B deficiency caused by a novel mutation involving multiple exons of the SP-B gene. 54 61
18558554 2008
12
Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD): defining novel phenotypes through hierarchical cluster analysis. 61 54
17431882 2007
13
Adult glycogenosis type II (Pompe's disease): morphological abnormalities in muscle and skin biopsies compared with acid alpha-glucosidase activity. 61 54
18176891 2007
14
Lung specific developmental expression of the Xenopus laevis surfactant protein C and B genes. 54 61
16798105 2007
15
Inherited surfactant protein-B deficiency and surfactant protein-C associated disease: clinical features and evaluation. 54 61
17142157 2006
16
Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. 54 61
16763223 2006
17
Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. 54 61
17011330 2006
18
Acute rhabdomyolysis complicating status asthmaticus in children: case series and review. 54 61
16912630 2006
19
Surfactant protein B deficiency: a rare cause of respiratory failure in a Lebanese newborn. 54 61
16521884 2006
20
Reversibility of lung inflammation caused by SP-B deficiency. 61 54
16024721 2005
21
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. 61 54
16005263 2005
22
Interstitial lung disease in children -- genetic background and associated phenotypes. 54 61
15819986 2005
23
[Neonatal respiratory failure associated with mutation in the surfactant protein C gene]. 54 61
15737281 2005
24
Actin mutations are one cause of congenital fibre type disproportion. 61 54
15468086 2004
25
C-reactive protein and body mass index predict outcome in end-stage respiratory failure. 54 61
15302742 2004
26
[Surfactant-associated proteins B and C: molecular biology and physiologic properties]. 54 61
15229816 2004
27
Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. 54 61
15190959 2004
28
Allelic heterogeneity of SMARD1 at the IGHMBP2 locus. 54 61
15108294 2004
29
Surfactant protein B deficiency in infants with respiratory failure. 61 54
15027668 2004
30
Severe infantile neuropathy with diaphragmatic weakness and its relationship to SMARD1. 61 54
14506069 2003
31
Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. 54 61
13129928 2003
32
[Respiratory diseases associated to surfactant proteins B and C deficiency]. 54 61
15279365 2003
33
Genetic influences and neonatal lung disease. 61 54
12667827 2003
34
Article reviewed: Sleep-disordered breathing and respiratory failure in acid maltase deficiency. 61 54
14592241 2002
35
Sleep-disordered breathing and respiratory failure in acid maltase deficiency. 61 54
11591850 2001
36
Elevated plasma surfactant protein-B predicts development of acute respiratory distress syndrome in patients with acute respiratory failure. 61 54
11520731 2001
37
Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. 54 61
10931427 2000
38
CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. 54 61
10934091 2000
39
Pulmonary surfactant metabolism in infants lacking surfactant protein B. 61 54
10696076 2000
40
Recurrent familial neonatal deaths: hereditary surfactant protein B deficiency. 61 54
11041444 2000
41
Hereditary surfactant protein B deficiency resulting from a novel mutation. 54 61
10663288 2000
42
Surfactant protein B deficiency: clinical, histological and molecular evaluation. 54 61
10365365 1999
43
Compound SFTPB 1549C-->GAA (121ins2) and 457delC heterozygosity in severe congenital lung disease and surfactant protein B (SP-B) deficiency. 61 54
10571948 1999
44
Clearance of Clara cell secretory protein 16 (CC16) and surfactant proteins A and B from blood in acute respiratory failure. 54 61
9817704 1998
45
A 60-year-old woman with weakness, fatigue, and acute respiratory failure: case report and discussion of the differential diagnosis. 61 54
9795552 1998
46
Regulation and function of pulmonary surfactant protein B. 61 54
9758711 1998
47
Deletion of thyroid transcription factor-1 gene in an infant with neonatal thyroid dysfunction and respiratory failure. 61 54
9565498 1998
48
Transient surfactant protein B deficiency in a term infant with severe respiratory failure. 61 54
9506635 1998
49
An early onset muscular dystrophy with diaphragmatic involvement, early respiratory failure and secondary alpha2 laminin deficiency unlinked to the LAMA2 locus on 6q22. 61 54
10726842 1998
50
[Chronic respiratory failure in a case with juvenile-onset acid alpha-glucosidase deficiency; successful therapy with nasal intermittent positive pressure ventilation (NIPPV)]. 61 54
8986097 1997

Variations for Respiratory Failure

ClinVar genetic disease variations for Respiratory Failure:

6 (show all 15)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MTM1 NC_000023.11:g.150583230_150648535del Deletion Pathogenic 812933 GRCh37: X:149751687-149817005
GRCh38:
2 PMS2 NM_000535.7(PMS2):c.1927C>T (p.Gln643Ter) SNV Pathogenic 91320 rs63751422 GRCh37: 7:6026469-6026469
GRCh38: 7:5986838-5986838
3 INPP5E NM_019892.6(INPP5E):c.1132C>T (p.Arg378Cys) SNV Pathogenic 400 rs121918130 GRCh37: 9:139327634-139327634
GRCh38: 9:136433182-136433182
4 CLCN6 NM_001286.5(CLCN6):c.1658A>G (p.Tyr553Cys) SNV Pathogenic 974617 GRCh37: 1:11894424-11894424
GRCh38: 1:11834367-11834367
5 CHAT NM_020549.4(CHAT):c.2081C>G (p.Ser694Cys) SNV Pathogenic 523529 rs201439531 GRCh37: 10:50872926-50872926
GRCh38: 10:49664880-49664880
6 CHAT NM_020549.4(CHAT):c.1061C>T (p.Thr354Met) SNV Pathogenic 523528 rs769234940 GRCh37: 10:50835781-50835781
GRCh38: 10:49627735-49627735
7 RYR1 NM_000540.2(RYR1):c.844C>T (p.Arg282Trp) SNV Likely pathogenic 374200 rs1057518970 GRCh37: 19:38939038-38939038
GRCh38: 19:38448398-38448398
8 ABCA3 NM_001089.3(ABCA3):c.875A>T (p.Glu292Val) SNV Likely pathogenic 203381 rs149989682 GRCh37: 16:2367764-2367764
GRCh38: 16:2317763-2317763
9 RYR1 NM_000540.2(RYR1):c.1186G>A (p.Glu396Lys) SNV Likely pathogenic 374199 rs774919231 GRCh37: 19:38942467-38942467
GRCh38: 19:38451827-38451827
10 MUSK NM_005592.4(MUSK):c.2365G>A (p.Gly789Ser) SNV Likely pathogenic 374195 rs1057518966 GRCh37: 9:113563023-113563023
GRCh38: 9:110800743-110800743
11 MUSK NM_005592.4(MUSK):c.1724T>C (p.Ile575Thr) SNV Likely pathogenic 190467 rs751889864 GRCh37: 9:113547944-113547944
GRCh38: 9:110785664-110785664
12 VANGL1 NM_138959.3(VANGL1):c.523C>T (p.Arg175Trp) SNV Uncertain significance 167818 rs142594314 GRCh37: 1:116206600-116206600
GRCh38: 1:115663979-115663979
13 TNFRSF13B NM_012452.2(TNFRSF13B):c.310T>C (p.Cys104Arg) SNV Uncertain significance 5302 rs34557412 GRCh37: 17:16852187-16852187
GRCh38: 17:16948873-16948873
14 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter) SNV Uncertain significance 599007 rs764412749 GRCh37: 19:42752628-42752628
GRCh38: 19:42248476-42248476
15 GATA4 NM_002052.5(GATA4):c.94G>C (p.Ala32Pro) SNV Uncertain significance 599008 rs773545065 GRCh37: 8:11565915-11565915
GRCh38: 8:11708406-11708406

Expression for Respiratory Failure

Search GEO for disease gene expression data for Respiratory Failure.

Pathways for Respiratory Failure

Pathways related to Respiratory Failure according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.3 SFTPD SFTPC SFTPB
2
Show member pathways
10.56 SFTPD SFTPC SFTPB ABCA3
3
Show member pathways
10.53 SFTPD SFTPC SFTPB

GO Terms for Respiratory Failure

Cellular components related to Respiratory Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.54 TTN SLC4A1 RYR1
2 clathrin-coated endocytic vesicle GO:0045334 9.33 SFTPD SFTPC SFTPB
3 lamellar body GO:0042599 9.32 SFTPC SFTPB
4 multivesicular body lumen GO:0097486 9.26 SFTPC SFTPB
5 I band GO:0031674 9.13 TTN RYR1 MTM1
6 alveolar lamellar body GO:0097208 8.8 SFTPC SFTPB ABCA3

Biological processes related to Respiratory Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 muscle cell cellular homeostasis GO:0046716 9.32 MTM1 GAA
2 striated muscle contraction GO:0006941 9.26 TTN GAA
3 cellular protein metabolic process GO:0044267 9.26 SFTPD SFTPC SFTPB ABCA3
4 surfactant homeostasis GO:0043129 9.16 SFTPD ABCA3
5 respiratory gaseous exchange GO:0007585 8.8 SFTPD SFTPC SFTPB

Molecular functions related to Respiratory Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.5 TTN RYR1 PMS2 MUSK IGHMBP2 CLCN6
2 chloride transmembrane transporter activity GO:0015108 8.62 SLC4A1 CLCN6

Sources for Respiratory Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....